Disease on EC 1.1.1.95 - phosphoglycerate dehydrogenase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Adenocarcinoma
Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.
Adenocarcinoma
Downregulation of phosphoglycerate dehydrogenase inhibits proliferation and enhances cisplatin sensitivity in cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3.
Adenocarcinoma
PHGDH Defines a Metabolic Subtype in Lung Adenocarcinomas with Poor Prognosis.
Adenocarcinoma
Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.
Adenocarcinoma of Lung
Erratum: Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum.
Adenocarcinoma of Lung
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
Adenocarcinoma of Lung
PHGDH Defines a Metabolic Subtype in Lung Adenocarcinomas with Poor Prognosis.
Adrenal Gland Neoplasms
Expression of Glucose Metabolism-Related Proteins in Adrenal Neoplasms.
Adrenocortical Adenoma
Expression of Glucose Metabolism-Related Proteins in Adrenal Neoplasms.
Adrenocortical Carcinoma
Expression of Glucose Metabolism-Related Proteins in Adrenal Neoplasms.
Alveolar Bone Loss
Tanshinone prevents alveolar bone loss in ovariectomized osteoporosis rats by up-regulating phosphoglycerate dehydrogenase.
Amebiasis
Artemether Exhibits Amoebicidal Activity against Acanthamoeba castellanii through Inhibition of the Serine Biosynthesis Pathway.
Arthrogryposis
Neu-Laxova syndrome presenting prenatally with increased nuchal translucency and cystic hygroma: The utility of exome sequencing in deciphering the diagnosis.
Brain Diseases
Early onset West syndrome with cerebral hypomyelination and reduced cerebral white matter.
Brain Ischemia
Cellular origin and regulation of D- and L-serine in in vitro and in vivo models of cerebral ischemia.
Brain Neoplasms
Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.
Breast Neoplasms
3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment.
Breast Neoplasms
A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.
Breast Neoplasms
Acetylation Stabilizes Phosphoglycerate Dehydrogenase by Disrupting the Interaction of E3 Ligase RNF5 to Promote Breast Tumorigenesis.
Breast Neoplasms
Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.
Breast Neoplasms
Bioinformatics analysis of the serine and glycine pathway in cancer cells.
Breast Neoplasms
Can small molecular inhibitors that stop de novo serine synthesis be used in cancer treatment?
Breast Neoplasms
Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis.
Breast Neoplasms
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer.
Breast Neoplasms
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
Breast Neoplasms
Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate.
Breast Neoplasms
Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype.
Breast Neoplasms
Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting.
Breast Neoplasms
In Vivo Evidence for Serine Biosynthesis-Defined Sensitivity of Lung Metastasis, but Not of Primary Breast Tumors, to mTORC1 Inhibition.
Breast Neoplasms
LncRNA PlncRNA-1 overexpression inhibits the growth of breast cancer by upregulating TGF-?1 and downregulating PHGDH.
Breast Neoplasms
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Breast Neoplasms
PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis.
Breast Neoplasms
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.
Breast Neoplasms
Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.
Breast Neoplasms
Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells.
Breast Neoplasms
Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth.
Breast Neoplasms
Prognostic significance of phosphoglycerate dehydrogenase in breast cancer.
Breast Neoplasms
Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer.
Carcinogenesis
Acetylation Stabilizes Phosphoglycerate Dehydrogenase by Disrupting the Interaction of E3 Ligase RNF5 to Promote Breast Tumorigenesis.
Carcinogenesis
Downregulation of phosphoglycerate dehydrogenase inhibits proliferation and enhances cisplatin sensitivity in cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3.
Carcinogenesis
Energy stress-induced linc01564 activates the serine synthesis pathway and facilitates hepatocellular carcinogenesis.
Carcinogenesis
EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Carcinogenesis
Gene expression changes in progression of cervical neoplasia revealed by microarray analysis of cervical neoplastic keratinocytes.
Carcinogenesis
Glyceraldehyde-3-phosphate dehydrogenase promotes liver tumorigenesis by modulating phosphoglycerate dehydrogenase.
Carcinogenesis
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
Carcinogenesis
High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer.
Carcinogenesis
Ixocarpalactone A from dietary tomatillo inhibits pancreatic cancer growth by targeting PHGDH.
Carcinogenesis
Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer.
Carcinogenesis
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Carcinogenesis
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.
Carcinogenesis
Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.
Carcinogenesis
Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.
Carcinogenesis
Rational Design of Selective Allosteric Inhibitors of PHGDH and Serine Synthesis with Anti-tumor Activity.
Carcinoma
Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation.
Carcinoma
Expression and clinical significance of phosphoglycerate dehydrogenase and squamous cell carcinoma antigen in cervical cancer.
Carcinoma
Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene.
Carcinoma
PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2?-Targeting Therapy for Renal Cell Carcinoma.
Carcinoma, Ductal
Prognostic significance of phosphoglycerate dehydrogenase in breast cancer.
Carcinoma, Embryonal
Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells.
Carcinoma, Hepatocellular
Role of cysteine in the dietary control of the expression of 3-phosphoglycerate dehydrogenase in rat liver.
Carcinoma, Hepatocellular
The modulation of serine metabolism in hepatoma 3924A during different phases of cellular proliferation in culture.
Carcinoma, Non-Small-Cell Lung
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
Carcinoma, Renal Cell
Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation.
Carcinoma, Renal Cell
PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2?-Targeting Therapy for Renal Cell Carcinoma.
Carcinoma, Squamous Cell
Expression and clinical significance of phosphoglycerate dehydrogenase and squamous cell carcinoma antigen in cervical cancer.
Colonic Neoplasms
Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.
Colonic Neoplasms
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
Colonic Neoplasms
Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene.
Colorectal Neoplasms
Can small molecular inhibitors that stop de novo serine synthesis be used in cancer treatment?
Colorectal Neoplasms
Increased Expression of PHGDH and Prognostic Significance in Colorectal Cancer.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Reduction of stratum corneum ceramides in Neu-Laxova syndrome caused by phosphoglycerate dehydrogenase deficiency.
Epilepsy
Phosphoglycerate dehydrogenase (PHGDH) deficiency without epilepsy mimicking primary microcephaly.
Fatty Liver
Downregulation of PHGDH expression and hepatic serine level contribute to the development of fatty liver disease.
Fatty Liver
Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption.
Gastritis
Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer.
Glioma
Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.
Glioma
Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
Glioma
Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.
Glucose Intolerance
Deletion of PHGDH in adipocytes improves glucose intolerance in diet-induced obese mice.
Hepatitis B, Chronic
[Cloning and expression of 3-phosphoglycerate dehydrogenase gene and its correlative antibodies in diagnosis of autoimmune hepatitis]
Hepatitis C, Chronic
[Cloning and expression of 3-phosphoglycerate dehydrogenase gene and its correlative antibodies in diagnosis of autoimmune hepatitis]
Hepatitis, Autoimmune
Detection of D-3-phosphoglycerate dehydrogenase autoantibodies in patients with autoimmune hepatitis: Clinical significance evaluation.
Hepatitis, Autoimmune
[Cloning and expression of 3-phosphoglycerate dehydrogenase gene and its correlative antibodies in diagnosis of autoimmune hepatitis]
Hyperglycinemia, Nonketotic
Reference data for cerebrospinal fluid and the utility of amino acid measurement for the diagnosis of inborn errors of metabolism.
Ichthyosis
Reduction of stratum corneum ceramides in Neu-Laxova syndrome caused by phosphoglycerate dehydrogenase deficiency.
Keloid
Upregulation of the NNP-1 (novel nuclear protein-1, D21S2056E) gene in keloid tissue determined by cDNA microarray and in situ hybridization.
Leukemia
High Fructose Drives the Serine Synthesis Pathway in Acute Myeloid Leukemic Cells.
Leukemia
Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene.
Leukemia
Reducing the serine availability complements the inhibition of the glutamine metabolism to block leukemia cell growth.
Liver Diseases
Downregulation of PHGDH expression and hepatic serine level contribute to the development of fatty liver disease.
Liver Diseases
Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption.
Lung Neoplasms
Differential Proteomic Analysis between Small Cell Lung Carcinoma (SCLC) and Pulmonary Carcinoid Tumors Reveals Molecular Signatures for Malignancy in Lung Cancer.
Lung Neoplasms
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
Lung Neoplasms
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Lymphatic Metastasis
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
Lymphatic Metastasis
PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer.
Lymphoma
Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene.
Melanoma
Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.
Melanoma
Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate.
Melanoma
Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells.
Melanoma
Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting.
Melanoma
p53 Protein-mediated regulation of phosphoglycerate dehydrogenase (PHGDH) is crucial for the apoptotic response upon serine starvation.
Melanoma
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.
Melanoma
Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.
Melanoma
Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition.
Microcephaly
3-phosphoglycerate dehydrogenase deficiency: a case report of a treatable cause of seizures.
Microcephaly
Congenital microcephaly and seizures due to 3-phosphoglycerate dehydrogenase deficiency: outcome of treatment with amino acids.
Microcephaly
Expanding the clinical spectrum of 3-phosphoglycerate dehydrogenase deficiency.
Microcephaly
Inactivation of the 3-phosphoglycerate dehydrogenase gene in mice: changes in gene expression and associated regulatory networks resulting from serine deficiency.
Microcephaly
Infantile Serine Biosynthesis Defect Due to Phosphoglycerate Dehydrogenase Deficiency: Variability in Phenotype and Treatment Response, Novel Mutations, and Diagnostic Challenges
Microcephaly
Molecular characterization of 3-phosphoglycerate dehydrogenase deficiency--a neurometabolic disorder associated with reduced L-serine biosynthesis.
Microcephaly
Neu-Laxova syndrome, an inborn error of serine metabolism, is caused by mutations in PHGDH.
Microcephaly
Phenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings.
Microcephaly
Phosphoglycerate dehydrogenase (PHGDH) deficiency without epilepsy mimicking primary microcephaly.
Microcephaly
V490M, a common mutation in 3-phosphoglycerate dehydrogenase deficiency, causes enzyme deficiency by decreasing the yield of mature enzyme.
Micrognathism
Neu-Laxova syndrome presenting prenatally with increased nuchal translucency and cystic hygroma: The utility of exome sequencing in deciphering the diagnosis.
Multiple Acyl Coenzyme A Dehydrogenase Deficiency
Characterization of ETFDH and PHGDH Mutations in a Patient with Mild Glutaric Aciduria Type II and Serine Deficiency.
Multiple Myeloma
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.
Multiple Myeloma
Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma.
Myocardial Infarction
DNA methylation and lipid metabolism: an EWAS of 226 metabolic measures.
Nasopharyngeal Carcinoma
3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment.
Nasopharyngeal Carcinoma
Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.
Nasopharyngitis
EBV-miR-BART1 is involved in regulating metabolism-associated genes in nasopharyngeal carcinoma.
Neoplasm Metastasis
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
Neoplasm Metastasis
High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer.
Neoplasm Metastasis
Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype.
Neoplasm Metastasis
Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition.
Neoplasm Metastasis
PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis.
Neoplasm Metastasis
PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer.
Neoplasm Metastasis
Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer.
Neoplasms
?-Ketothioamide Derivatives: A Promising Tool to Interrogate Phosphoglycerate Dehydrogenase (PHGDH).
Neoplasms
A retrospective overview of PHGDH and its inhibitors for regulating cancer metabolism.
Neoplasms
An epitope tag alters phosphoglycerate dehydrogenase structure and impairs ability to support cell proliferation.
Neoplasms
Anti-alcohol abuse drug disulfiram inhibits human PHGDH via disruption of its active tetrameric form through a specific cysteine oxidation.
Neoplasms
Artemether Exhibits Amoebicidal Activity against Acanthamoeba castellanii through Inhibition of the Serine Biosynthesis Pathway.
Neoplasms
Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.
Neoplasms
Can small molecular inhibitors that stop de novo serine synthesis be used in cancer treatment?
Neoplasms
Challenges and Opportunities in the Development of Serine Synthetic Pathway Inhibitors for Cancer Therapy.
Neoplasms
Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation.
Neoplasms
Control of nutrient stress-induced metabolic reprogramming by PKC? in tumorigenesis.
Neoplasms
Correction for Mullarky et al., Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers.
Neoplasms
Coupling between d-3-phosphoglycerate dehydrogenase and d-2-hydroxyglutarate dehydrogenase drives bacterial l-serine synthesis.
Neoplasms
Dimerization of PHGDH via the catalytic unit is essential for its enzymatic function.
Neoplasms
Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors.
Neoplasms
Discovery of novel inhibitors of human phosphoglycerate dehydrogenase by activity-directed combinatorial chemical synthesis strategy.
Neoplasms
Downregulation of phosphoglycerate dehydrogenase inhibits proliferation and enhances cisplatin sensitivity in cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3.
Neoplasms
Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs).
Neoplasms
EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Neoplasms
Expression of metabolism-related proteins in invasive lobular carcinoma: comparison to invasive ductal carcinoma.
Neoplasms
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer.
Neoplasms
Gene expression changes in progression of cervical neoplasia revealed by microarray analysis of cervical neoplastic keratinocytes.
Neoplasms
Glyceraldehyde-3-phosphate dehydrogenase promotes liver tumorigenesis by modulating phosphoglycerate dehydrogenase.
Neoplasms
Gold-nanofève surface-enhanced Raman spectroscopy visualizes hypotaurine as a robust anti-oxidant consumed in cancer survival.
Neoplasms
High level PHGDH expression in breast is predominantly associated with keratin 5-positive cell lineage independently of malignancy.
Neoplasms
High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer.
Neoplasms
Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate.
Neoplasms
Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype.
Neoplasms
Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers.
Neoplasms
Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting.
Neoplasms
Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma.
Neoplasms
Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells.
Neoplasms
Inhibition of Serine Metabolism Promotes Resistance to Cisplatin in Gastric Cancer.
Neoplasms
Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.
Neoplasms
In Vivo Evidence for Serine Biosynthesis-Defined Sensitivity of Lung Metastasis, but Not of Primary Breast Tumors, to mTORC1 Inhibition.
Neoplasms
Ixocarpalactone A from dietary tomatillo inhibits pancreatic cancer growth by targeting PHGDH.
Neoplasms
Kinesin family member 15 promotes cancer stem cell phenotype and malignancy via reactive oxygen species imbalance in hepatocellular carcinoma.
Neoplasms
Knockdown of PHGDH potentiates 5-FU cytotoxicity in gastric cancer cells via the Bcl-2/Bax/caspase-3 signaling pathway.
Neoplasms
Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition.
Neoplasms
Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
Neoplasms
Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer.
Neoplasms
Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis.
Neoplasms
Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene.
Neoplasms
Parkin on serine: a Parkinson disease gene suppresses serine synthesis in cancer.
Neoplasms
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Neoplasms
PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis.
Neoplasms
PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer.
Neoplasms
Phosphoglycerate dehydrogenase (PHGDH) inhibitors: a comprehensive review 2015-2020.
Neoplasms
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.
Neoplasms
Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.
Neoplasms
Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells.
Neoplasms
Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer.
Neoplasms
Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth.
Neoplasms
Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.
Neoplasms
Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma.
Neoplasms
Phosphoglycerate dehydrogenase: potential therapeutic target and putative metabolic oncogene.
Neoplasms
Protein interactome of the deamidase phosphoribosylformylglycinamidine synthetase (PFAS) by LC-MS/MS.
Neoplasms
Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
Neoplasms
Serine biosynthesis is a metabolic vulnerability in IDH2-driven breast cancer progression.
Neoplasms
Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy.
Neoplasms
Shift from stochastic to spatially-ordered expression of serine-glycine synthesis enzymes in 3D microtumors.
Neoplasms
Structure-Activity Relationships (SARs) of ?-Ketothioamides as Inhibitors of Phosphoglycerate Dehydrogenase (PHGDH).
Neoplasms
Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma.
Neoplasms
Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer.
Neuroblastoma
Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect.
Neuroblastoma
Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma.
Obesity
Deletion of PHGDH in adipocytes improves glucose intolerance in diet-induced obese mice.
Obesity
Target identification of the novel antiobesity agent tungstate in adipose tissue from obese rats.
Optic Atrophy
Early onset West syndrome with cerebral hypomyelination and reduced cerebral white matter.
Osteoporosis
Tanshinone prevents alveolar bone loss in ovariectomized osteoporosis rats by up-regulating phosphoglycerate dehydrogenase.
Osteosarcoma
Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma.
Osteosarcoma
Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma.
Ovarian Neoplasms
In situ Metabolic Profiling of Ovarian Cancer Tumor Xenografts: A Digital Pathology Approach.
Ovarian Neoplasms
PHGDH Is Upregulated at Translational Level and Implicated in Platin-Resistant in Ovarian Cancer Cells.
Ovarian Neoplasms
Proteomic alterations of fibroblasts induced by ovarian cancer cells reveal potential cancer targets.
Pancreatic Neoplasms
Ixocarpalactone A from dietary tomatillo inhibits pancreatic cancer growth by targeting PHGDH.
Pancreatic Neoplasms
Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer.
Pancreatic Neoplasms
PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer.
Pancreatic Neoplasms
Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.
Parathyroid Neoplasms
3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment.
Parkinson Disease
Parkin on serine: a Parkinson disease gene suppresses serine synthesis in cancer.
phosphoglycerate dehydrogenase deficiency
3-Phosphoglycerate dehydrogenase deficiency and 3-phosphoserine phosphatase deficiency: inborn errors of serine biosynthesis.
phosphoglycerate dehydrogenase deficiency
3-phosphoglycerate dehydrogenase deficiency in a patient with West syndrome.
phosphoglycerate dehydrogenase deficiency
3-phosphoglycerate dehydrogenase deficiency: a case report of a treatable cause of seizures.
phosphoglycerate dehydrogenase deficiency
3-Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis.
phosphoglycerate dehydrogenase deficiency
3-phosphoglycerate dehydrogenase deficiency: description of two new cases in Tunisia and review of the literature.
phosphoglycerate dehydrogenase deficiency
A Serine Synthesis Defect Presenting With a Charcot-Marie-Tooth-Like Polyneuropathy.
phosphoglycerate dehydrogenase deficiency
Beneficial effects of L-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency.
phosphoglycerate dehydrogenase deficiency
Congenital microcephaly and seizures due to 3-phosphoglycerate dehydrogenase deficiency: outcome of treatment with amino acids.
phosphoglycerate dehydrogenase deficiency
Continuing education in neurometabolic disorders--serine deficiency disorders.
phosphoglycerate dehydrogenase deficiency
Early onset West syndrome with cerebral hypomyelination and reduced cerebral white matter.
phosphoglycerate dehydrogenase deficiency
Effect of selectively knocking down key metabolic genes in Müller glia on photoreceptor health.
phosphoglycerate dehydrogenase deficiency
Expanding the clinical spectrum of 3-phosphoglycerate dehydrogenase deficiency.
phosphoglycerate dehydrogenase deficiency
Fatal cerebral edema associated with serine deficiency in CSF.
phosphoglycerate dehydrogenase deficiency
Genetic disorders of gamma-aminobutyric acid, glycine, and serine as causes of epilepsy.
phosphoglycerate dehydrogenase deficiency
Hypomyelination and reversible white matter attenuation in 3-phosphoglycerate dehydrogenase deficiency.
phosphoglycerate dehydrogenase deficiency
Infantile Serine Biosynthesis Defect Due to Phosphoglycerate Dehydrogenase Deficiency: Variability in Phenotype and Treatment Response, Novel Mutations, and Diagnostic Challenges
phosphoglycerate dehydrogenase deficiency
Neurotransmitters in 3-phosphoglycerate dehydrogenase deficiency.
phosphoglycerate dehydrogenase deficiency
Novel mutations in 3-phosphoglycerate dehydrogenase (PHGDH) are distributed throughout the protein and result in altered enzyme kinetics.
phosphoglycerate dehydrogenase deficiency
Phenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings.
phosphoglycerate dehydrogenase deficiency
Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells.
phosphoglycerate dehydrogenase deficiency
Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency.
phosphoglycerate dehydrogenase deficiency
Reduction of stratum corneum ceramides in Neu-Laxova syndrome caused by phosphoglycerate dehydrogenase deficiency.
phosphoglycerate dehydrogenase deficiency
Reference data for cerebrospinal fluid and the utility of amino acid measurement for the diagnosis of inborn errors of metabolism.
phosphoglycerate dehydrogenase deficiency
Serine Synthesis via PHGDH Is Essential for Heme Production in Endothelial Cells.
phosphoglycerate dehydrogenase deficiency
Treatment with amino acids in serine deficiency disorders.
phosphoglycerate dehydrogenase deficiency
V490M, a common mutation in 3-phosphoglycerate dehydrogenase deficiency, causes enzyme deficiency by decreasing the yield of mature enzyme.
phosphoglycerate dehydrogenase deficiency
[Genetic and phenotypic analysis of a patient with phosphogylcerate dehydrogenase deficiency].
phosphoserine phosphatase deficiency
3-Phosphoglycerate dehydrogenase deficiency and 3-phosphoserine phosphatase deficiency: inborn errors of serine biosynthesis.
phosphoserine phosphatase deficiency
Continuing education in neurometabolic disorders--serine deficiency disorders.
phosphoserine phosphatase deficiency
Treatment with amino acids in serine deficiency disorders.
Polyneuropathies
A Serine Synthesis Defect Presenting With a Charcot-Marie-Tooth-Like Polyneuropathy.
Retinal Diseases
Serine biosynthesis defect due to haploinsufficiency of PHGDH causes retinal disease.
ring-type e3 ubiquitin transferase deficiency
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Sarcoma, Ewing
Can small molecular inhibitors that stop de novo serine synthesis be used in cancer treatment?
Sarcoma, Ewing
EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Seizures
3-phosphoglycerate dehydrogenase deficiency: a case report of a treatable cause of seizures.
Seizures
Beneficial effects of L-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency.
Seizures
Congenital microcephaly and seizures due to 3-phosphoglycerate dehydrogenase deficiency: outcome of treatment with amino acids.
Seizures
Genetic disorders of gamma-aminobutyric acid, glycine, and serine as causes of epilepsy.
Seizures
Molecular characterization of 3-phosphoglycerate dehydrogenase deficiency--a neurometabolic disorder associated with reduced L-serine biosynthesis.
Seizures
Phenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings.
Seizures
V490M, a common mutation in 3-phosphoglycerate dehydrogenase deficiency, causes enzyme deficiency by decreasing the yield of mature enzyme.
Spasms, Infantile
3-phosphoglycerate dehydrogenase deficiency in a patient with West syndrome.
Spasms, Infantile
Early onset West syndrome with cerebral hypomyelination and reduced cerebral white matter.
Starvation
Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer.
Starvation
p53 Protein-mediated regulation of phosphoglycerate dehydrogenase (PHGDH) is crucial for the apoptotic response upon serine starvation.
Starvation
Role of cysteine in the dietary control of the expression of 3-phosphoglycerate dehydrogenase in rat liver.
Starvation
Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy.
Stomach Neoplasms
Inhibition of Serine Metabolism Promotes Resistance to Cisplatin in Gastric Cancer.
Stomach Neoplasms
Knockdown of PHGDH potentiates 5-FU cytotoxicity in gastric cancer cells via the Bcl-2/Bax/caspase-3 signaling pathway.
Stomach Neoplasms
Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer.
Strabismus
3-phosphoglycerate dehydrogenase deficiency: a case report of a treatable cause of seizures.
Thyroid Cancer, Papillary
High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer.
Thyroid Carcinoma, Anaplastic
Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer.
Thyroid Neoplasms
High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer.
Triple Negative Breast Neoplasms
Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
Triple Negative Breast Neoplasms
Serine Synthesis Helps Hypoxic Cancer Stem Cells Regulate Redox.
Tuberculosis
A Novel Mechanism for Substrate Inhibition in Mycobacterium tuberculosis D-3-Phosphoglycerate Dehydrogenase.
Tuberculosis
Crystal structure of Mycobacterium tuberculosis D-3-phosphoglycerate dehydrogenase: extreme asymmetry in a tetramer of identical subunits.
Tuberculosis
D-3-Phosphoglycerate dehydrogenase from Mycobacterium tuberculosis is a link between the Escherichia coli and mammalian enzymes.
Tuberculosis
Determinants of substrate specificity in D-3-phosphoglycerate dehydrogenase. Conversion of the M. tuberculosis enzyme from one that does not use ?-ketoglutarate as a substrate to one that does.
Tuberculosis
Kinetic Evidence of a Noncatalytic Substrate Binding Site That Regulates Activity in Legionella pneumophilal-Serine Dehydratase.
Tuberculosis
Kinetic, mutagenic, and structural homology analysis of L-serine dehydratase from Legionella pneumophila.
Tuberculosis
Regulation of Mycobacterium tuberculosis D-3-phosphoglycerate dehydrogenase by phosphate-modulated quaternary structure dynamics and a potential role for polyphosphate in enzyme regulation.
Tuberculosis
Role of the Anion-Binding Site in Catalysis and Regulation of Mycobacterium tuberculosis d-3-Phosphoglycerate Dehydrogenase.
Tuberculosis
Structural analysis of substrate and effector binding in Mycobacterium tuberculosis D-3-phosphoglycerate dehydrogenase.
Tuberculosis
Structure of L-serine dehydratase from Legionella pneumophila: novel use of the C-terminal cysteine as an intrinsic competitive inhibitor.
Urinary Bladder Neoplasms
Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation.
Uterine Cervical Neoplasms
3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment.
Uterine Cervical Neoplasms
Expression and clinical significance of phosphoglycerate dehydrogenase and squamous cell carcinoma antigen in cervical cancer.
Uterine Cervical Neoplasms
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
Varicocele
Down regulating PHGDH affects the lactate production of sertoli cells in varicocele.
Virus Diseases
Serine metabolism antagonizes antiviral innate immunity by preventing ATP6V0d2-mediated YAP lysosomal degradation.
html completed